Impulsivity With Borderline Personality Disorder/tMS

Status Recruiting

Clinical Trial Summary

This is a prospective, randomized, double-blind, parallel-group controlled trial. The aim of this research project is to compare the clinical benefits achieved in patients with Borderline Personality Disorder (BPD) following two types of intervention: ccPAS active or ccPAS sham.

Clinical Trial Description

Borderline personality disorder (BPD) is a mental disorder characterized by unstable interpersonal relationships, emotional lability and marked impulsivity. The latter manifests itself through risky behaviors such as substance abuse, self-harm and suicidal behavior. Studies suggest that 1.3% of the general population suffers from BPD. However, in clinical settings, BPD patients represent 20% of all inpatients in psychiatric wards and up to 50% of patients hospitalized in emergency departments following a suicide attempt (SA). Moreover, it is estimated that nearly 84% of BPD patients will make at least one SA in their lifetime and up to 10% of them will die by suicide, a rate 50 times higher than the general population. Impulsivity, reflected in difficulties holding back action or stopping an action that has already begun, is one of the key symptoms of BPD. Recent advances in non-invasive brain stimulation have led to the emergence of a new stimulation protocol known as Paired Cortico-Cortical Associative Stimulation (ccPAS), which consists of repeating paired stimulations using two TMS coils placed respectively on two cortical regions of interest. Paired stimulations' repetition induces plasticity by strengthening synaptic connectivity between the two targeted regions. The aim of this project is to test the efficacy of a ccPAS protocol in enhancing effective connectivity between the IFC and pre-SMA in order to reduce impulsivity in BPD patients. The Sponsor hypothesized that one ccPAS session, using two coils simultaneously, targeting the IFC and pre-SMA with a 'physiological' inter-stimulus interval of 4ms will improve motor inhibition abilities (reduce SSRT), compared to the group receiving 'control' ccPAS (100ms inter-stimulus interval (ccPAS100-ms)). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05942651
Study type	Interventional
Source	Hôpital le Vinatier
Contact	POULET Emmanuel, PUPH
Phone	0437915565
Email	emmanuel.poulet@chu-lyon.fr
Status	Recruiting
Phase	N/A
Start date	January 8, 2024
Completion date	September 20, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04856449` - DBT Skills Plus EMDR for BPD and Trauma	N/A
Active, not recruiting	`NCT04587518` - Five Factor Model Treatment for Borderline Personality Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Completed	`NCT03677037` - The Short-Term MBT Project	Phase 3
Not yet recruiting	`NCT05989529` - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed	`NCT02518906` - Evaluation of AIT Study	N/A
Completed	`NCT02068326` - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial	N/A
Recruiting	`NCT04296604` - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations	N/A
Completed	`NCT02108990` - Acetaminophen and Social Processes	Phase 2
Terminated	`NCT02149823` - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations	Phase 1
Not yet recruiting	`NCT01683136` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder	N/A
Completed	`NCT02988037` - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study	N/A
Completed	`NCT01635556` - Evaluation of a Modified Dialectical Behavior Therapy Program	N/A
Completed	`NCT02397031` - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder	N/A
Terminated	`NCT01103180` - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder	Phase 2
Terminated	`NCT01212588` - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)	Phase 2
Terminated	`NCT00539188` - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD	Phase 2
Recruiting	`NCT05398627` - Neurofeedback for Borderline Personality Disorder	N/A
Recruiting	`NCT03994510` - SHame prOpensity in bOrderline Personality Disorder	N/A
Recruiting	`NCT06005129` - Personality Change Study for Borderline Personality Disorder	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impulsivity With Borderline Personality Disorder/tMS — IMPULSE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms